Assessment
tumor
BLOOD, TUMOR
Patients were screened within 28 days before the first day of study drug administration (week 1 day 1 [W1D1]). Throughout the study, patient conditions were assessed by the physician and evaluated for efficacy, safety, and health-related quality of life (HRQoL) at scheduled visits. Computed tomography or magnetic resonance imaging of the chest/abdomen/pelvis were performed at screening, 8-week intervals (± 7 days) after W1D1 until the end of the 12-month period, and at 12-week intervals after completion of the first 12 months. Blood and urine samples were obtained every 4 weeks after W1D1.Questionnaires were collected every 4 weeks after W1D1 until the end of the 9-week period. After week 9, questionnaires were collected every 4 weeks (± 7 days) up to 6 months, and every 8 weeks (± 7 days) until the last tumor assessment.